Results of Auspex Pharmaceuticals' Phase 3 Registration Trial of SD-809 to be Presented at AAN Annual Meeting
March 27, 2015 07:00 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., March 27, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for people...
Auspex Pharmaceuticals Reports Fourth Quarter 2014 Results and Business Highlights
March 16, 2015 16:01 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for people...
Auspex to Present at the Cowen Healthcare Conference
February 23, 2015 06:30 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Pharmaceuticals Completes Enrollment in a Pivotal Clinical Trial of SD-809 in Tardive Dyskinesia
February 03, 2015 06:30 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex to Present at the 2015 Leerink Global Healthcare Conference
February 02, 2015 16:00 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
January 28, 2015 16:00 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Announces Pricing of Follow on Offering
January 23, 2015 07:27 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Announces Proposed Public Offering of Common Stock
January 21, 2015 16:32 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 21, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Tourette Syndrome in the Pediatric Population
January 14, 2015 13:34 ET
|
Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan. 14, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a biopharmaceutical company dedicated to developing innovative medicines for people with movement...
Auspex Pharmaceuticals Announces SD-1077 Program for the Potential Treatment of Parkinson's Disease and Related Movement Disorders
January 12, 2015 09:19 ET
|
Auspex Pharmaceuticals, Inc.
Auspex to Acquire Remaining Worldwide Rights to SD-1077 Through Purchase of Imphar AG
Clinical Proof-Of-Concept Data for SD-1077 Versus Levodopa Expected in 2016
LA JOLLA, Calif., Jan. 12, 2015...